News
-
Regulators enter drug pricing debate
almost 8 years ago by Gerry Kennedy
By Anjali Shukla The Chinese authorities have come down strongly on the issue of drug costs, slashing the prices of some expensive medicines by up to two-thirds. The Chinese regulators have cut the cost of GlaxoSmithKline's (LSE: GSK) hepatitis B drug Viread would fall to 490 yuan ($75) a month from 1,500 yuan, and AstraZeneca's (LSE: AZ...
Read More -
Exciting Manufacturing, Quality, R&D and Process Developement Engineer roles in Ireland
almost 8 years ago by John Reid
I have many exciting opportunities with leading Multinational Medical Device companies all across Ireland. You do not have to have Medical Device experience either, should you have a Manufacturing/Quality background then we can begin talking. In strict confidence please feel free to call me on 01 2302400 or email johnr@rftgroup.ie Manufacturing ...
Read More -
Allergan's on the M&A hunt, but don't confuse it with Valeant:
almost 8 years ago by Gerry Kennedy
Allergan may have recorded most of its recent growth through dealmaking rather than good, old-fashioned R&D. But that doesn’t mean it deserves comparisons to embattled drugmaker Valeant, its CEO insists. As chief exec Brent Saunders told the Financial Times, his company has been “historically disciplined” when it comes to taking big price inc...
Read More -
Cancer drugs get even pricier
almost 8 years ago by Gerry Kennedy
Rising cancer drug prices have sparked outrage from patients, doctors and payers. Now, new information is adding fuel to the fire. Launch prices for cancer meds have increased over the years, and pharma continues to hike prices even after they’re approved for a broader patient pool, two new studies show. In one study, researchers looked at 32...
Read More